Amgen Inc. said its experimental and novel treatment for advanced melanoma met the main goal of a late-stage clinical trial by demonstrating a durable response in significantly more patients than a comparison treatment, the New York Times and Reuters report.

For reprint and licensing requests for this article, CLICK HERE.